Nozinan (Levomepromazine)

Levomepromazine, the active ingredient in Nozinan, is a phenothiazine antipsychotic presented as a tablet for oral use. It is employed in the management of severe agitation, psychotic disorders, and nausea in palliative care settings. GNH USA supplies Nozinan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Nozinan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Levomepromazine is a low‑potency phenothiazine that acts on multiple neurotransmitter pathways, providing relief in several clinical situations.

- Severe agitation and psychosis: helps calm patients with acute or chronic psychiatric disturbances. - Nausea and vomiting in palliative care: reduces refractory symptoms when other anti‑emetics fail. - Pre‑operative sedation: used to tranquilize patients before surgery. - Painful muscle spasm: alleviates muscle rigidity associated with certain neurological conditions. - Delirium in terminal illness: improves comfort and reduces distress. - Anxiety disorders : offers short‑term relief of severe anxiety when other agents are unsuitable.

Levomepromazine may cause a range of adverse reactions, from mild to potentially life‑threatening.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Dry mouth: reduced salivation leading to a sticky sensation. - Constipation: slowed gastrointestinal motility. - Orthostatic hypotension: drop in blood pressure when standing. - Blurred vision: temporary visual disturbances. - Weight gain: increase in body weight over time.

Serious or Rare Side Effects: - Extrapyramidal symptoms: muscle rigidity, tremor, or uncontrolled movements. - Neuroleptic malignant syndrome: high fever, muscle rigidity, and autonomic instability. - Severe hypotension: dangerous drop in blood pressure. - Cardiac arrhythmias: irregular heart rhythms that may require monitoring. - Torsades de pointes: a specific type of ventricular tachycardia. - Agranulocytosis: dangerously low white‑blood cell count.

When prescribing Levomepromazine, clinicians should consider several safety aspects.

- Assess baseline cardiovascular status: patients with existing heart disease may be at higher risk of hypotension. - Monitor for extrapyramidal symptoms: early detection can prevent progression to severe movement disorders. - Evaluate liver and kidney function: impaired metabolism may increase drug exposure. - Use caution in the elderly: increased sensitivity to sedative and anticholinergic effects. - Avoid abrupt discontinuation: taper gradually to reduce withdrawal phenomena. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Levomepromazine can interact with a variety of medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other central nervous system depressants: may cause excessive sedation or respiratory depression. - Antihypertensive agents: additive blood‑pressure‑lowering effects can lead to severe hypotension. - QT‑prolonging drugs: combined use raises the risk of torsades de pointes.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs: may intensify dry‑mouth and constipation. - CYP2D6 inhibitors: can increase